NCT06918054 Hepatoprotective for Children and Adolescent With Acute Lymphoblastic Leukemia
| NCT ID | NCT06918054 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Ain Shams University |
| Condition | Leukaemia (Acute) |
| Study Type | INTERVENTIONAL |
| Enrollment | 42 participants |
| Start Date | 2023-11-17 |
| Primary Completion | 2025-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 42 participants in total. It began in 2023-11-17 with a primary completion date of 2025-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This current study will implement a proposed whole program of monitoring and prevention acute hepatic injury during the time of induction chemotherapy in children and adolescent with ALL.
Eligibility Criteria
Inclusion Criteria: Children and adolescents aged from 2 to 18 years newly diagnosed with acute lymphoblastic leukemia during induction phase of chemotherapy treated at Ain Shams Exclusion Criteria: Known chronic liver disease.
Contact & Investigator
Manal El-Sayed, MD
STUDY CHAIR
Faculty of Medicine Ain Shams University
Frequently Asked Questions
Who can join the NCT06918054 clinical trial?
This trial is open to participants of all sexes, aged 2 Years or older, up to 18 Years, studying Leukaemia (Acute). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06918054 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06918054 currently recruiting?
Yes, NCT06918054 is actively recruiting participants. Contact the research team at fatmaebeid@med.asu.edu.eg for enrollment information.
Where is the NCT06918054 trial being conducted?
This trial is being conducted at Cairo, Egypt, Cairo, Egypt.
Who is sponsoring the NCT06918054 clinical trial?
NCT06918054 is sponsored by Ain Shams University. The principal investigator is Manal El-Sayed, MD at Faculty of Medicine Ain Shams University. The trial plans to enroll 42 participants.